Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation.
A synthetic thrombin inhibitor, MD-805, was used to anticoagulate 15 patients after cardiovascular surgery (CVS). A mean infusion rate of 0.71 +/- 0.1 (SD) microgram/kg . min maintained an activated coagulation time of about 150 sec in all patients, and significantly prolonged both activated partial thromboplastin time and prothrombin time. MD-805 was also administered to ten patients with disseminated intravascular coagulation (DIC), eight of whom had not responded to either heparin or gabexate mesilate (FOY), and eight of whom had circulating antithrombin III levels below 20 mg/dl. MD-805 therapy was successful in nine DIC patients. These results recommend MD-805 anticoagulant therapy after CVS and for treatment of DIC, especially when circulating levels of antithrombin III are low.
D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D001120:Arginine / Q000031:analogs & derivatives; D002318:Cardiovascular Diseases / Q000601:surgery; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control*; D005260:Female; D016670:Gabexate; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010875:Pipecolic Acids / Q000627:therapeutic use*; D011182:Postoperative Care; D013449:Sulfonamides
D006146:Guanidines; D010875:Pipecolic Acids; D013449:Sulfonamides; D016670:Gabexate; D000990:Antithrombin III; D001120:Arginine; C031942:argatroban